{"id":"treatment-a","rwe":[{"pmid":"41866236","year":"2026","title":"Ethical tensions in legally mandated substance use treatment: A scoping review of participant perspectives.","journal":"Addiction (Abingdon, England)"},{"pmid":"41861192","year":"2026","title":"Effectiveness of ultrasonography-guided pericapsular nerve group block in patients with adhesive capsulitis resistant to conservative treatment: A prospective observational study.","journal":"Medicine"},{"pmid":"41837374","year":"2026","title":"Using Observational Data to Investigate Cognitive Outcomes of Obstructive Sleep Apnea Treatment: A Scoping Review.","journal":"The journals of gerontology. Series A, Biological sciences and medical sciences"},{"pmid":"41831222","year":"2026","title":"Real World Outcomes of a Condensed Classroom-Based Cognitive Behavioral Therapy for Cancer-Related Cognitive Impairment.","journal":"Psycho-oncology"},{"pmid":"41829936","year":"2026","title":"Diet Quality Is Not Associated with Malnutrition, Low Muscle Mass and Sarcopenia During Lung Cancer Treatment: A Cross-Sectional Study.","journal":"Nutrients"}],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00270413","NCT00169988","NCT00197951","NCT01258088","NCT04919122","NCT03425266","NCT03885089","NCT00728468","NCT05780541","NCT06254495","NCT00563524","NCT01150903","NCT05407805","NCT05067439","NCT00633386","NCT02351856","NCT03424005","NCT03351751","NCT01184001","NCT06918002","NCT01243151","NCT03400254","NCT00003673","NCT01677065","NCT00652028"],"aliases":[],"patents":[],"pricing":[],"allNames":"treatment a","offLabel":[],"timeline":[{"date":"1999","type":"neutral","milestone":"Phase 2 Initiated","description":"Phase 2 trial (CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse) — Leukemia"},{"date":"2010","type":"neutral","milestone":"Phase 1 Initiated","description":"Phase 1 trial (Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis) — Psoriasis"},{"date":"2022","type":"negative","milestone":"Phase 3 Initiated","description":"Phase 3 trial (PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)) — COVID-19. Trial terminated early."}],"aiSummary":"I cannot provide the requested summary because the drug information for Treatment A is incomplete. The FDA mechanism text and approved indications are missing from your submission. Please provide the complete drug name, mechanism of action details, and approved indications to generate an accurate summary.","brandName":"Treatment A","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Single 875 mg dose of mevrometostat standard tablet formulation","explanation":"","oneSentence":"Single 875 mg dose of mevrometostat standard tablet formulation","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"treatment-a","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Healthy","phase":"discontinued","trialId":"","patients":null,"diseaseId":"unknown","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00270413","phase":"Phase 2","title":"SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer","status":"Completed","sponsor":"Universitaire Ziekenhuizen KU Leuven","isPivotal":false,"enrollment":19,"indication":"Metastatic Breast Cancer","completionDate":"2009-03","primaryEndpoint":"This study tests the hypothesis that SU11248 can delay tumor progression after tumor mass reduction by taxanes."},{"nctId":"NCT00169988","phase":"N/A","title":"Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms","status":"Completed","sponsor":"Northwell Health","isPivotal":false,"enrollment":8,"indication":"Prodromal Schizophrenia","completionDate":"","primaryEndpoint":"The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to"},{"nctId":"NCT00197951","phase":"Phase 3","title":"Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism","status":"Completed","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","isPivotal":false,"enrollment":60,"indication":"Depression","completionDate":"","primaryEndpoint":"Alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of dopamine, norepinephrine and serotonin neurotransmission, during early recovery."},{"nctId":"NCT01258088","phase":"Phase 1","title":"Safety Study of Ointment for the Treatment of Plaque-type Psoriasis","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":16,"indication":"Plaque-type Psoriasis","completionDate":"2010-12","primaryEndpoint":"The purpose of this study is to determine how much drug is absorbed throughout the body after being applied to the skin."},{"nctId":"NCT04919122","phase":"N/A","title":"Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma","status":"Active Not Recruiting","sponsor":"Duke University","isPivotal":false,"enrollment":468,"indication":"Metastatic Renal Cell Carcinoma","completionDate":"2026-12","primaryEndpoint":"ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in th"},{"nctId":"NCT03425266","phase":"N/A","title":"The Pain App Study: A Novel Shared Decision Making Tool for People With Chronic Pain","status":"Completed","sponsor":"Shared Decision Making Resources","isPivotal":false,"enrollment":80,"indication":"Chronic Pain","completionDate":"2018-06","primaryEndpoint":"The investigators seek to understand the preferences, goals, and perspectives of patients with chronic pain and their health care providers (HCPs) to create a patient-centered decision support tool."},{"nctId":"NCT03885089","phase":"N/A","title":"Infliximab Biosimilar for Intravenous Drip Infusion 100 mg \"Pfizer\" Drug Use Investigation (Psoriasi","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":10,"indication":"Psoriasis Vulgaris","completionDate":"2024-03","primaryEndpoint":"To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg \"Pfizer\" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythr"},{"nctId":"NCT00728468","phase":"Phase 1","title":"A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patien","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":16,"indication":"Advanced Malignant Solid Tumors","completionDate":"2011-04","primaryEndpoint":"Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextrometh"},{"nctId":"NCT05780541","phase":"Phase 3","title":"PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"Terminated","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":58,"indication":"COVID-19","completionDate":"2022-04","primaryEndpoint":"This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in people who have been hospitalized with the infection."},{"nctId":"NCT06254495","phase":"Phase 1","title":"A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers","status":"Active Not Recruiting","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":57,"indication":"Hodgkin Disease","completionDate":"2028-04","primaryEndpoint":"This clinical trial is studying lymphoma."},{"nctId":"NCT00563524","phase":"Phase 1","title":"Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis","status":"Completed","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":76,"indication":"Psoriasis","completionDate":"2010-06","primaryEndpoint":"The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis"},{"nctId":"NCT01150903","phase":"N/A","title":"Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor","status":"Completed","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":98832,"indication":"Erectile Dysfunction","completionDate":"2010-07","primaryEndpoint":"Erectile dysfunction (ED) has been identified as an independent risk factor for existing cardiovascular disease, preceding a major cardiovascular event by an average of about 5 years."},{"nctId":"NCT05407805","phase":"N/A","title":"A Study to Learn About Sickle Cell Disease In Adult Patients","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":98,"indication":"Sickle Cell Disease","completionDate":"2024-06","primaryEndpoint":"The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in people with SCD who are on treatment that will change SCD and those not on such a"},{"nctId":"NCT05067439","phase":"Phase 1","title":"A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole i","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":26,"indication":"Healthy Participants","completionDate":"2022-02","primaryEndpoint":"This is a Phase 1, open-label, multiple dose, single fixed-sequence, 2-period study to evaluate the effect of abrocitinib on the pharmacokinetics (PK) of caffeine, efavirenz and omeprazole in healthy "},{"nctId":"NCT00633386","phase":"Phase 4","title":"Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics Af","status":"Completed","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":200,"indication":"Arthroscopy","completionDate":"","primaryEndpoint":"To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo."},{"nctId":"NCT02351856","phase":"Phase 2","title":"A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":8,"indication":"LMNA-Related Dilated Cardiomyopathy","completionDate":"2020-12","primaryEndpoint":"This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMN"},{"nctId":"NCT03424005","phase":"Phase 1/2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metas","status":"Recruiting","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":792,"indication":"Metastatic Breast Cancer","completionDate":"2030-09","primaryEndpoint":"This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer."},{"nctId":"NCT03351751","phase":"Phase 1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":19,"indication":"Healthy Volunteers","completionDate":"2018-02","primaryEndpoint":"The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple repeat oral doses of PF-06372865 in healthy adult subjects."},{"nctId":"NCT01184001","phase":"Phase 1","title":"A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":16,"indication":"Rheumatoid Arthritis","completionDate":"2010-09","primaryEndpoint":"In this study, a 10 mg tasocitinib (CP-690,550) tablet will be administered to healthy subjects on two separate dosing occasions."},{"nctId":"NCT06918002","phase":"Phase 3","title":"Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After ","status":"Recruiting","sponsor":"Intergroupe Francophone du Myelome","isPivotal":false,"enrollment":824,"indication":"Multiple Myeloma, Newly Diagnosed","completionDate":"2036-05","primaryEndpoint":"This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT."},{"nctId":"NCT01243151","phase":"Phase 1","title":"Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolem","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":68,"indication":"Hypercholesterolemia","completionDate":"2011-10","primaryEndpoint":"The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia."},{"nctId":"NCT03400254","phase":"Phase 1/2","title":"Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACI","status":"Withdrawn","sponsor":"Abramson Cancer Center at Penn Medicine","isPivotal":false,"enrollment":0,"indication":"Breast Cancer","completionDate":"2019-08","primaryEndpoint":"This clinical trial will assess the safety and early efficacy of the role of gedatolisib and hydroxychloroquine in early-stage breast cancer patients with residual disease and evidence of disseminated"},{"nctId":"NCT00003673","phase":"Phase 2","title":"CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":55,"indication":"Leukemia","completionDate":"1999-03","primaryEndpoint":"RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die."},{"nctId":"NCT01677065","phase":"N/A","title":"A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-rele","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":14,"indication":"Healthy","completionDate":"2012-10","primaryEndpoint":"To determine whether the bioavailability of the controlled-release test formulation is at least as high as that for the commercial reference drug."},{"nctId":"NCT00652028","phase":"Phase 2","title":"Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects","status":"Completed","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":69,"indication":"Intubated and Mechanically Ventilated Pediatric Subjects","completionDate":"2010-04","primaryEndpoint":"The objective of this study is to characterize the pharmacokinetic and pharmacodynamic profile of dexmedetomidine administered as an intravenous loading dose followed by a continuous intravenous infus"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL4297904"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":26,"withResults":7},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}